AASLD is pleased to announce the selection of David E. Cohen, MD, PhD, FAASLD (left), as the next Editor-in-Chief of HEPATOLOGY. Dr. Cohen will serve a five-year editorial term starting in January 2017 and ending in December 2021. He currently serves as Director of Hepatology at Brigham and Women’s Hospital, Director of the Harvard-Massachusetts Institute of Technology Division of Health Sciences and Technology, and is the Robert H. Ebert Professor of Medicine at Harvard Medical School. Dr. Cohen recently shared the following thoughts on his upcoming term as editor.
It is an honor because HEPATOLOGY is the principal publication of AASLD, which has played a major role in my career since medical school. This is an opportunity to give back to the journal that has helped me so much. It will be an intellectual challenge to identify and publish the best clinical and basic research in the field of liver disease. I also look forward to facilitating communication among members of the hepatology community both within the society and beyond.
HEPATOLOGY remains the premier journal for liver disease research. The high quality, high impact papers published in HEPATOLOGY continue to define the state-of-the-art in basic and clinical liver disease research, which has over the years led to significant advances in the treatment and prevention of liver disease.
I plan to uphold the long tradition of excellence in publishing that has been the hallmark of HEPATOLOGY since the journal’s inception. This includes attracting the best in both basic and clinical liver research, as well as high quality reviews, commentaries, and clinical observations. In addition, I plan to keep practitioners current through the publication and dissemination of Practice Guidelines. I also hope to facilitate robust communication among HEPATOLOGY authors and readers by leveraging technology and social media.